Thus, our findings suggest that PRKG2 and the phosphorylation of Ser259‐MYRF can serve as potentially therapeutic targets for mitigating demyelination in HD, and perhaps in other diseases with demyelination as well. This evidence concerns the gene PRKG2 and Huntington disease.